Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19911562 | 0.89 | HCAR3 (0.52) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL30447942 | 0.86 | HCAR3 (0.55) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL19911536 | 0.86 | HCAR3 (0.55) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL10712046 | 0.83 | HCAR3 (0.46) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL19911535 | 0.77 | HCAR3 (0.55) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL19848521 | 0.77 | HCAR3 (0.63) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL19911369 | 0.76 | ALDH1A1 (0.51) | HCAR3MEN1KMT2AMAPTLMNA | |
| SCHEMBL5382257 | 0.76 | GLS (0.53) | MEN1KMT2AMAPTLMNACYP1A2 | |
| SCHEMBL19911585 | 0.76 | HCAR3 (0.62) | HCAR3MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL21991683 | 0.76 | HCAR3 (0.62) | HCAR3MEN1KMT2ACYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180062213-A1 | Nonaqueous Electrolyte and Nonaqueous Secondary Battery | BPTF, BRD4, KCNN2 | HCAR3 4636/4885MEN1 1058/4885KMT2A 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.